Siemens Enters Collaboration Agreement with Pfizer

(Tarrytown, NY, USA) entered into a master collaboration agreement with Pfizer Inc. (New York, NY, USA) to design, develop, and commercialize diagnostic tests for therapeutic products across Pfizer's pipeline. Under the agreement, Siemens will be one of Pfizer's collaboration partners to develop and provide in vitro companion diagnostics. The aim is eventual global commercialization with Pfizer products.

Companion diagnostic tests are clinical tests linked to a specific drug or therapy intended to help physicians make more correct personalized treatment decisions for patients. When used in the drug development process, companion diagnostics may help pharmaceutics companies improve patient selection and treatment monitoring, determine the preferred therapy dosing for patients, and establish a protocol to help maximize the treatment benefit for patients.

The partnership will leverage Siemens' worldwide leadership in providing clinical diagnostic solutions for hospital and reference laboratories, specialty laboratories, and point-of-care (POC) settings (including clinics and physician offices) to help enable diagnostics development.

"Our relationship with Pfizer marks a major milestone in Siemens' personalized medicine strategy," commented Dr. Trevor Hawkins, senior vice president, strategy & innovations, diagnostics division, Siemens Healthcare. John Hubbard, senior vice president and worldwide head of development operations at Pfizer emphasized that, "Companion diagnostics are an important enabler of targeted therapies for patients."

The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a leader in medical imaging, laboratory diagnostics, medical information technology, and hearing aids. Siemens offers its customers products and solutions for patient care from a single source, from prevention and early detection, to diagnosis, and finally treatment and aftercare.

Related Links:
Siemens Healthcare Diagnostics Inc.
Pfizer Inc.